U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing

You may not qualify if:

• Prior exposure to any Janus kinase (JAK) inhibitor
• Investigational study drug within 4 weeks (or 5 half-lives, whichever is longer) prior to enrollment
• ANC < 1.000/mm3, ALC < 500/mm3 or hemoglobin < 8g/dl
• Any contraindication to perform MRI
• Anti-CCP- Antibody positivity
• Any other autoimmune or inflammatory disease such as SLE, PSS, MCTD, Behcet disease, vasculitis or autoimmune hepatitis
• malignancy risk factors (e.g. current malignancy or history of malignancy)
• Any severe active infection, e.g. hepatitis B or C, SARS-CoV 2 (COVID 19), or active tuberculosis as defined by a positive Quantiferon TB-test. If presence of latent tuberculosis is established then treatment according to local guidelines must have been initiated prior to enrollment
• Have a known history of serious infections (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months
• Immunocompromised patients
• Uncontrolled severe concomitant disease
• Pregnant or lactating females
• Known hypersensitivity to upadacitinib or any other drug components
• Requirement for immunization with live vaccine during the trial period or within 4 weeks preceding baseline
• History of venous thrombosis or pulmonary embolism, inherited coagulation disorder, planned major surgery, immobilisation
• +8 more criteria